TR4
Not specified (Selective β2-adrenoceptor antagonist)
Key Facts
About Trio Medicines
Trio Medicines is a private, preclinical/clinical-stage biotech company developing a small pipeline of novel small molecules, originating from the work of Nobel Laureate Sir James Black. Its lead asset, netazepide, is a gastrin/CCK2 receptor antagonist with Orphan Drug designation for gastric neuroendocrine tumors (g-NETs) and is seeking a partner for Phase 3 development. The company is wholly funded and supported by its parent, Hammersmith Medicines Research (HMR) Ltd, a major European CRO, which has conducted all of Trio's early trials to date. Trio's strategy involves advancing its pipeline through internal resources while actively seeking development and commercialization partnerships for its key programs.
View full company profile